[Effect of dioxadet on tumors transplanted to the brain].

Abstract	A newly-developed antitumor drug Dioxadet is capable of passing the blood-brain barrier. The specific activity of rat brain tissue ranged 8-55% of that of blood at different periods after intraperitoneal injection of 14C-labelled Dioxadet. Dioxadet treatment of mice and rats bearing intracranially-transplanted L1210 leukemia and glioma 35 was followed by a 38-48 and 29% increase in survival, respectively.
Authors	A N Stukov, M V Korsakov, T N Khrapova, N E Kil'maeva, B O Kraĭz
Journal	Voprosy onkologii (Vopr Onkol) Vol. 32 Issue 10 Pg. 64-7 ( 1986) ISSN: 0507-3758 [Print] Russia (Federation)
Vernacular Title	Vliianie dioksadéta na opukholi, perevitye v golovnoĭ mozg.
PMID	3776129 (Publication Type: English Abstract, Journal Article)
Chemical References	Antineoplastic Agents Triazines dioxadet
Topics	Animals Antineoplastic Agents (therapeutic use) Blood-Brain Barrier (drug effects) Brain Neoplasms (drug therapy, secondary) Glioma (drug therapy) Leukemia L1210 (drug therapy) Mice Mice, Inbred DBA Neoplasm Transplantation Rats Triazines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!